Cellectis (CLLS) Non Operating Income (2015 - 2026)
Cellectis (CLLS) posted quarterly Non Operating Income of -$7.4 million for Q1 2026, down 88.68% year-over-year from -$65.8 million in Q1 2025, and down 143.52% quarter-over-quarter from $17.1 million in Q4 2025.
Cellectis (CLLS) Non Operating Income (2015 - 2026) Analysis & Trends
Cellectis' Non Operating Income history runs 12 years deep, the most recent figure standing at -$7.4 million for Q1 2026.
- In Q1 2026, Non Operating Income fell 88.68% year-over-year to -$7.4 million; the TTM figure through Mar 2026 stood at -$11.9 million (down 60.65% YoY), while the FY2025 annual figure was -$34.9 million, down 253.29% from the prior year.
- Non Operating Income for Q1 2026 stood at -$7.4 million, down from $17.1 million in the prior quarter.
- The five-year high for Non Operating Income was $17.1 million in Q4 2024, with the low at -$26.3 million in Q1 2024.
- The 5-year median for Non Operating Income is -$5.8 million (2023), against an average of -$5.3 million.
- Peak annual rise in Non Operating Income reached 301.04% in 2022, while the deepest fall reached 737.74% in 2022.
- Cellectis' Non Operating Income stood at -$20.0 million in 2022, then plunged by 30.87% to -$26.1 million in 2023, then surged by 165.54% to $17.1 million in 2024, then changed by 0.0% to $17.1 million in 2025, then slumped by 143.52% to -$7.4 million in 2026.
- Business Quant data shows CLLS's Non Operating Income at -$7.4 million in Q1 2026, $17.1 million in Q4 2025, and -$7.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -139.24 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 12.40 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -51.63 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -53.64 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Cellectis | 306.61 Mn | 120.95 Mn | - | 7.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -7.45 Mn |
| Dec 31, 2025 | 17.12 Mn |
| Sep 30, 2025 | -7.45 Mn |
| Jun 30, 2025 | -14.15 Mn |
| Mar 31, 2025 | -3.95 Mn |
| Dec 31, 2024 | 17.12 Mn |
| Sep 30, 2024 | -12.35 Mn |
| Jun 30, 2024 | -8.25 Mn |
| Mar 31, 2024 | -26.28 Mn |
| Dec 31, 2023 | -26.12 Mn |
| Sep 30, 2023 | 3.30 Mn |
| Jun 30, 2023 | -5.84 Mn |
| Mar 31, 2023 | -4.40 Mn |
| Dec 31, 2022 | -19.96 Mn |
| Sep 30, 2022 | 1.81 Mn |
| Jun 30, 2022 | 8.30 Mn |
| Mar 31, 2022 | -912,000.00 |
| Dec 31, 2021 | 3.13 Mn |
| Sep 30, 2021 | 2.30 Mn |
| Jun 30, 2021 | -4.13 Mn |